Welcome to our dedicated page for IMMNOV news (Ticker: IMMNOV), a resource for investors and traders seeking the latest updates and insights on IMMNOV stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IMMNOV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IMMNOV's position in the market.
Immunovia, a diagnostics company based in Sweden, announces it will host an event on May 3, 2023, to discuss the adoption of its IMMrayTM PanCan-d test, which is the world's first blood test for early detection of pancreatic cancer. The event will feature key opinion leaders including David Bakelman, Cheryl Meguid, and Rosario Ligresti, who will engage in panel discussions.
The company will also outline its commercialization strategy in the U.S., a critical market with an addressable size of approximately 1.8 million individuals annually. The IMMrayTM PanCan-d test started commercialization in August 2021. This event reflects Immunovia's commitment to improving diagnostic solutions for pancreatic cancer.
On April 20, 2023, Immunovia (Nasdaq: IMMNOV) announced its participation in a webinar titled "Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer," hosted by the National Pancreas Foundation on April 26, 2023, at 7:00 pm ET. The webinar will feature presentations by Lara Sucheston-Campbell, VP of Clinical and Medical Affairs at Immunovia, and Dr. Rosario Ligresti from Hackensack University Medical Center. It aims to discuss the clinical application of novel biomarkers and liquid biopsies for early pancreatic cancer detection, covering sensitivity, specificity, and future detection strategies. Immunovia's IMMray™ PanCan-d test is the only blood test specifically for early pancreatic cancer detection, with a large addressable market in the USA.
Immunovia (Nasdaq Stockholm: IMMNOV) has announced the appointment of Karl Stone as Chief Operating Officer, effective March 1, 2023. This leadership change aligns with the company’s focus on enhancing the US commercialization of its IMMray™ PanCan-d test, a blood-based diagnostic for early pancreatic cancer detection. Stone brings over 25 years of experience in IVD systems and bioprocessing. His role will involve leading R&D and Product Management to enhance efficiency. The IMMray™ PanCan-d test is critical for addressing a significant market with an estimated addressable size of 1.8 million individuals annually in the USA.
